Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.
Elisabetta PatornoSebastian SchneeweissChandrasekar GopalakrishnanDavid MartinJessica M FranklinPublished in: Diabetes care (2019)
In a nonrandomized RWD study, we found that linagliptin has noninferior risk of a composite cardiovascular outcome compared with glimepiride.